ReportsnReports.com adds “The Chinese Pharmaceutical Market to 2024 - Commercial & Strategic developments in the Chinese Pharmaceutical Market to 2024” report to its research database.
From 2008 to 2013, China’s OTC drugs market reported an average growth of 15% with the market reaching $20.6bn in 2013 up from to $11bn in 2008 but what will it be this year? Next year? and in 5 years time?
The OTC drugs market in China was characterised by a late start, but fast growth, along with huge potential in comparison to that of the mature OTC markets in many western countries. Your company should be benefiting from this market access – and this is only the OTC market – what has the growth been throughout the whole Chinese pharma sector? This report will tell you.
China’s pharmaceutical sales growth is based on economic growth in the country: This has resulted in increased healthcare expenditure internally, and increased manufacture and export. Increasing urbanisation, disposable income, aging population, health education, lifestyle diseases and government investments and initiatives for healthcare infrastructure improvement have helped the market growth considerably. Have you captured enough of the Chinese market?
Inquire for a discount on this report @ http://www.reportsnreports.com/contacts/Discount.aspx?name=277045.
Annually, an average of $190 is spent for the treatment of diabetes, per patient, in China. By 2030, in China, diabetes is expected to cost Yuan 173.4bn ($28 bn) a year. China is expected to top the world’s diabetes tables both in terms of sheer numbers and population prevalence. This is true across a range of complaints and products types – your company must capture a segment of this market TODAY.
Anti-Counterfeiting and anti-corruption – How the Chinese market is changing
Counterfeit drugs are successfully introduced in to the lengthy and complicated delivery chain because of the highly fragmented nature of the market. A lack of regular inspections by any recognised drug enforcement / regulatory bodies, again due to the highly fragmented nature of production, allows counterfeit / poor quality drugs into the Chinese pharma market. Moreover, wide spread corruption also helps the distribution of counterfeit drugs. What are the Chinese regulators, and the global manufacturers doing to change this? Find out in this unique report.
Buy a copy of this report @ http://www.reportsnreports.com/Purchase.aspx?name=277045.
Increased inward investment from multiple ‘Big Pharma’ companies has driven investment in R&D centres as well as opportunities for Chinese graduates. Many graduates are staying in China; those that have left now have jobs to return to. Are you producing enough of your products in China? Increase your profitability through this channel.
Domestically, increased levels of health insurance, increased health education, rising numbers of hospitals and increased per capita income have all driven the Chinese pharmaceutical market.
- Increase in healthcare expenditure per capita, from $157in 2008 to $278 in 2011
- Increasing income and population. The middle class population reached 400m in 2010 and is expected to reach 500m by 2015
- In 2012, the central government alone invested CNY 24.3bn ($3.9bn) to improve health service infrastructure.
- Key life style changes, which have accelerated the diseases such as obesity, diabetes, cardiovascular, chronic respiratory diseases
- The over 65 population has increased to 9.1% of the total population in China in 2011 from 8.3% in 2008
This report also breaks down the market in terms of current drugs and products that occupy the Chinese market at present; examining the key prescription and OTC drugs that drive the Chinese market. In addition to this crucial information this report offers analysis and opinion on current R&D in the country alongside in depth analysis of the evolving, global inward investment.
Discover exactly what the industry leaders are doing TODAY
Industry information sourced exclusively for this report. This information is not available anywhere else
Utilising primary and secondary research sources, GMR Data have interviewed leading specialists within big pharma, R&D, wholesalers, distributors, marketeers and key organisations specialising in access to the Chinese market, as well as Chinese pharmaceutical companies accessing the global market. From these interviews we have selected original, exclusive, transcribed interviews with leading specialists in their field – This information is not available anywhere else.
This GMR Data report is the single tool to equip you with the latest trends in all pharma sectors and why all stakeholders demand development of the Chinese pharmaceutical market. This report will arm you with all you and your company require to develop, price, launch and market a product in China, or compete with a Chinese product launched in your market.
With over 160 pages, and over 140+ charts, tables, figures and graphs, this dedicated specialist report will ensure you remain equipped and fully informed, to succeed in this competitive market.
- Capture or increase your foothold in the Chinese market TODAY
- Establish partnerships to manufacture, distribute or develop Chinese products
- Establish anti-counterfeiting
systems today to increase market size and revenue
Complete report available @ http://www.reportsnreports.com/reports/277045-the-chinese-pharmaceutical-market-to-2024-commercial-strategic-developments-in-the-chinese-pharmaceutical-market-to-2024.html.
ReportsnReports.com is an online market research reports library of 350,000+ in-depth studies of over 5000 micro markets. Call +1 888 391 5441 with your research requirements or email the details on firstname.lastname@example.org and we would be happy to help you find the business intelligence that you need. Not limited to the Pharmaceuticals (http://www.reportsnreports.com/market-research/pharmaceuticals/) industry, ReportsnReports.com offers research studies on agriculture, medical devices, healthcare, environment, banking and financial services, biotechnology, energy and power, water and much more.